Brett Hagen Sells 1,915 Shares of Kalaris Therapeutics (NASDAQ:KLRS) Stock

Key Points

• CAO Brett Hagen sold 1,915 shares of Kalaris Therapeutics on March 20 at an average price of $6.72, for a total value of $12,868.80, per an SEC filing.
• Shares traded down 1.1% to $6.50 on light volume (41,026) and the company reported quarterly EPS of −$0.44, beating consensus −$0.56 by $0.12; market cap is about $149.05 million with a 52‑week range of $2.14–$12.26.
• Institutional investors own 66.05% of the stock with several funds initiating stakes recently, and analysts show a consensus rating of "Moderate Buy" with an average price target of $14.00.

Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) CAO Brett Hagen sold 1,915 shares of the stock in a transaction that occurred on Friday, March 20th. The shares were sold at an average price of $6.72, for a total value of $12,868.80. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Kalaris Therapeutics Stock Down 1.1%

Shares of NASDAQ:KLRS traded down $0.07 during trading on Monday, reaching $6.50. The stock had a trading volume of 41,026 shares, compared to its average volume of 65,230. The stock has a fifty day simple moving average of $9.34 and a two-hundred day simple moving average of $7.34. Kalaris Therapeutics Inc. has a 52 week low of $2.14 and a 52 week high of $12.26. The firm has a market capitalization of $149.05 million, a price-to-earnings ratio of -1.54 and a beta of -0.13.

Kalaris Therapeutics (NASDAQ:KLRS - Get Free Report) last posted its quarterly earnings data on Tuesday, March 17th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.12.

Institutional Investors Weigh In On Kalaris Therapeutics

Several hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd acquired a new stake in Kalaris Therapeutics during the second quarter worth about $65,000. Fortis Capital Advisors LLC acquired a new position in Kalaris Therapeutics in the 3rd quarter valued at approximately $231,000. Belpointe Asset Management LLC bought a new stake in shares of Kalaris Therapeutics in the 3rd quarter worth approximately $231,000. Johnson Financial Group Inc. bought a new stake in shares of Kalaris Therapeutics in the 3rd quarter worth approximately $58,000. Finally, Bridgeway Capital Management LLC acquired a new stake in shares of Kalaris Therapeutics during the 3rd quarter worth approximately $130,000. Institutional investors own 66.05% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on KLRS. Citigroup reaffirmed an "outperform" rating on shares of Kalaris Therapeutics in a research report on Thursday, December 18th. Chardan Capital started coverage on Kalaris Therapeutics in a research note on Tuesday, December 23rd. They set a "buy" rating and a $19.00 target price for the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Kalaris Therapeutics in a report on Monday, December 29th. Finally, Wall Street Zen raised Kalaris Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday, March 15th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Kalaris Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $14.00.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.